AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial

AstraZeneca said on Monday that patients lost 10.5% of their body weight after 26 weeks in a mid-stage trial of ​its experimental obesity pill, as the drugmaker seeks to challenge Novo Nordisk and Eli Lilly in the ‌fast-growing weight-loss market.